Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1420 ARTÍCULOS , VIENDO DEL 706 AL 720

Therapeutic Efficacy of Mesenchymal Stem Cells (MSCs) on Alzheimer's Disease: Review of Clinical Results

Kim AL, Lee WK, Kwon S, Han I, Choi BH.

Tissue Eng Regen Med. 2026 Apr;23(3):343-365. doi: 10.1007/s13770-025-00782-1. Epub 2026 Jan 14.

Evaluation of ASC as a therapeutic target for Alzheimer's disease

Clayton WB, Kulas JA, Liu J, Walia N, Rangel-Barajas C, Johnson T, Zhang J, Huang K, Mesecar AD, Dage JL, Lamb BT, Palkowitz AD, Richardson TI.

Alzheimers Dement. 2026 Jan;22(1):e71104. doi: 10.1002/alz.71104.

Targeting the Nrf2/HO-1 aixs: A therapeutic strategy against regulated cell death in Alzheimer's disease

Wang Z, Feng W, Li X, Yun X, Wu S, Du L, Wang H.

Ageing Res Rev. 2026 Apr;116:103035. doi: 10.1016/j.arr.2026.103035. Epub 2026 Jan 28.

Insulin Signaling in Alzheimer's Disease: Association with Brain Insulin Resistance

Pliszka M, Szablewski L.

Int J Mol Sci. 2026 Jan 26;27(3):1222. doi: 10.3390/ijms27031222.

Clinical meaningfulness of anti-amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region

Chen C, Lee JH, Park KH, Hu CJ, Mok V, Senanarong V, Inaba K, Dash A.

Alzheimers Dement. 2026 Feb;22(2):e71230. doi: 10.1002/alz.71230.

Ferroptosis and Alzheimer's disease: a new insight into neurodegeneration

Quan Y, Liu H, Zhang M, Li M, He B, Wang K, Huang X, Zhou S, Han Z, Fan H.

Front Immunol. 2026 Feb 6;17:1701767. doi: 10.3389/fimmu.2026.1701767. eCollection 2026.

The Double-Edged Sword Effect of the Fibrinolytic System in Alzheimer's Disease

Tang M, Liang M, Zhang X, Hong C, Ye L.

Cell Mol Neurobiol. 2026 Feb 27;46(1):66. doi: 10.1007/s10571-026-01699-6.

The evolving landscape of amyloid-targeting therapies in Alzheimer's disease: progress and challenges

Zhang B, Yu X, Zhang X.

Neurol Sci. 2026 Feb 28;47(3):304. doi: 10.1007/s10072-026-08893-w.

Serotonergic psychedelics as epigenetic modulators: A paradigm shift in Alzheimer's disease therapeutics

Gojani EG, Farzin H, Sutherland RJ, Mohajerani MH.

Neurosci Biobehav Rev. 2026 May;184:106619. doi: 10.1016/j.neubiorev.2026.106619. Epub 2026 Feb 28.

Implication of the thalamus in sleep alterations observed in Alzheimer's disease

Burnet-Merlin C, Hay YA, Brécier A.

Alzheimers Dement. 2026 Mar;22(3):e71242. doi: 10.1002/alz.71242.

Amyloid precursor protein is a subunit of microglial Hv1 channels

Zhao R, Goldstein SA.

Curr Opin Immunol. 2026 Jun;100:102751. doi: 10.1016/j.coi.2026.102751. Epub 2026 Mar 3.

Non-pharmacological interventions for sleep disorders in patients with Alzheimer's disease: An integrative review

Montenegro MLV, Santos AP, Pacheco ABV, Kato CFPA, Souza LG, Ribeiro MMC, Oliveira PJ, Lucena Raulino VA, Rabelo WL, da Silva TCN, Resende LT, Barbosa BJAP.

Sleep Med. 2026 Jun;142:108874. doi: 10.1016/j.sleep.2026.108874. Epub 2026 Feb 26.

lncRNAs: key player in Aβ deposition

Wang RM, Wang ZQ.

RNA Biol. 2026 Dec;23(1):1-16. doi: 10.1080/15476286.2026.2639017. Epub 2026 Mar 5.

PAR-1 in Alzheimer's Disease: Pathophysiological Insights and Mechanistic Perspectives

Neha, Mandal S, Sharma V, Dhindsa J, Aran KR.

Curr Med Sci. 2026 Apr;46(2):297-306. doi: 10.1007/s11596-026-00175-y. Epub 2026 Mar 5.

TREM2 and microglial immunity in Alzheimer's disease: mechanisms, genetics, and therapeutic opportunities

Wang T, Liu X, Wang X, Hua F, Yan L.

Front Immunol. 2026 Feb 18;17:1739875. doi: 10.3389/fimmu.2026.1739875. eCollection 2026.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias